Quicklogic Corp (QUIK) Names Michael R. Farese as New Chairman

QuickLogic Corporation (NASDAQ: QUIK), a developer of ultra-low power multi-core voice-enabled SoCs, embedded FPGA IP, and Endpoint AI solutions, today announced the appointment of Michael R. Farese as the Chairman of the Board of Directors, effective December 6, 2019 to replace E. Thomas Hart, who passed away on December 3, 2019.

Michael R. Farese (Ph.D.) has been serving as a member of QuickLogic's Board of Directors since April 2008, most recently as the lead independent director, and brings to the position a deep understanding of consumer products, converged devices and wireless markets. Dr. Farese has over 40 years of broad technology industry experience, and has held high-level leadership positions in multiple companies including chief executive officer, chief scientist, senior vice president of engineering, and chief technology officer. His business acumen and strong technical and strategic planning skills bring an invaluable perspective to the Board.

"I am pleased to continue to serve QuickLogic as its Chairman of the Board of Directors. QuickLogic has tremendous opportunity going forward in the exciting areas of AI, IoT, SAS for sensor endpoints, embedded FPGA, and low power SoCs and I look forward to helping the company realize that opportunity" said Farese.

"Mike has been instrumental and tremendously supportive in our transition to becoming a platform company," said Brian Faith, QuickLogic president and CEO. "He brings a strong operational background from systems to semiconductors to software, as well as proven experience on public company Boards. The entire Board of Directors is confident that Mike's transition from lead independent director to Chairman of the Board will be seamless, enabling us to continue our laser focus on executing our strategic initiatives and financial goals."

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• Canopy Growth (CGC) Announces CBI Conversion to Exchangeable Shares, Appoints New Board
• Verastem Oncology (VSTM) Appoints John Hayslip to Chief Medical Officer